PriceTargets.com logo

NASDAQ:NTEC - Intec Pharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.00
  • Forecasted Upside: 229.11 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.95 As of 03/8/2021 01:05 PM ET
▼ -0.02 (-0.50%)
1 month | 3 months | 12 months
Get New Intec Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTEC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTEC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$13.00
▲ +229.11% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Intec Pharma in the last 3 months. The average price target is $13.00, with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 229.11% upside from the last price of $3.95.
Hold
The current consensus among 4 contributing investment analysts is to hold stock in Intec Pharma. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/14/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/15/2020Roth CapitalReiterated RatingNeutralLow
i
Rating by S. Henry at Roth Capital
12/9/2020LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$13.00High
i
10/9/2020HC WainwrightReiterated RatingHoldLow
i
Rating by R. Selvaraju at HC Wainwright
8/17/2020HC WainwrightReiterated RatingNeutralHigh
i
Rating by R. Selvaraju at HC Wainwright
8/6/2020Maxim GroupReiterated RatingHoldMedium
i
5/18/2020LADENBURG THALM/SH SHReiterated RatingHoldHigh
i
4/13/2020HC WainwrightReiterated RatingHoldHigh
i
Rating by Ram Selvaraju at HC Wainwright
12/12/2019HC WainwrightReiterated RatingHoldMedium
i
Rating by Ram Selvaraju at HC Wainwright
12/2/2019HC WainwrightReiterated RatingHoldHigh
i
Rating by Ram Selvaraju at HC Wainwright
10/11/2019Roth CapitalDowngradeBuy ➝ Neutral$200.00 ➝ $20.00Low
i
Rating by S. Henry at Roth Capital
8/12/2019LADENBURG THALM/SH SHReiterated RatingHoldHigh
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
8/7/2019HC WainwrightDowngradeBuy ➝ NeutralMedium
i
Rating by Ram Selvaraju at HC Wainwright
7/22/2019OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/22/2019LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
7/22/2019Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason McCarthy at Maxim Group
6/20/2019HC WainwrightSet Price TargetBuy$320.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/20/2019Maxim GroupReiterated RatingBuy$240.00High
i
6/20/2019LADENBURG THALM/SH SHReiterated RatingBuy$300.00Low
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
5/28/2019HC WainwrightSet Price TargetBuy$320.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/16/2019LADENBURG THALM/SH SHReiterated RatingBuyHigh
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
5/1/2019LADENBURG THALM/SH SHReiterated RatingBuyLow
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
2/28/2019LADENBURG THALM/SH SHReiterated RatingBuy$300.00Low
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
2/22/2019OppenheimerSet Price TargetBuy$300.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/19/2019Maxim GroupReiterated RatingBuy$240.00High
i
1/29/2019LADENBURG THALM/SH SHReiterated RatingBuy$240.00N/A
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
1/4/2019HC WainwrightReiterated RatingBuy$320.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
12/10/2018HC WainwrightReiterated RatingBuy$320.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/2/2018OppenheimerSet Price TargetBuy$300.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/15/2018OppenheimerSet Price TargetBuy$300.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/24/2018HC WainwrightSet Price TargetBuy$320.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
10/5/2018Roth CapitalInitiated CoverageBuy$170.00High
i
Rating by R. Leboyer at Roth Capital
9/30/2018OppenheimerSet Price TargetBuy$300.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/16/2018HC WainwrightSet Price TargetBuy$320.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/15/2018OppenheimerSet Price TargetBuy$300.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/26/2018Roth CapitalReiterated RatingBuy$200.00Low
i
Rating by R. Leboyer at Roth Capital
5/24/2018OppenheimerSet Price TargetBuy$300.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/22/2018HC WainwrightSet Price TargetBuy$320.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/7/2018HC WainwrightSet Price TargetBuy$320.00Low
i
Rating by Ram Selvaraju at HC Wainwright
4/11/2018OppenheimerSet Price TargetBuy$300.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/26/2018Maxim GroupBoost Price TargetBuy ➝ Buy$160.00 ➝ $240.00Medium
i
Rating by Jason McCarthy at Maxim Group
3/21/2018OppenheimerReiterated RatingBuyLow
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/18/2018HC WainwrightSet Price TargetBuy$320.00Low
i
Rating by Ram Selvaraju at HC Wainwright
3/13/2018OppenheimerSet Price TargetBuy$300.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/12/2018HC WainwrightReiterated RatingBuy$320.00Medium
i
Rating by R. Selvaraju at HC Wainwright
3/7/2018OppenheimerSet Price TargetBuy$300.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/28/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ BuyMedium
i
2/26/2018HC WainwrightInitiated CoverageBuy ➝ BuyHigh
i
Rating by R. Selvaraju at HC Wainwright
12/18/2017OppenheimerSet Price TargetBuy$300.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/17/2017Maxim GroupSet Price TargetBuy$180.00 ➝ $160.00N/A
i
Rating by Jason Kolbert at Maxim Group
11/16/2017OppenheimerSet Price TargetBuy$300.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/13/2017OppenheimerSet Price TargetBuy$300.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/21/2017CIBCReiterated RatingOutperform ➝ Outperform$200.00 ➝ $300.00Medium
i
9/21/2017OppenheimerBoost Price TargetOutperform$200.00 ➝ $300.00High
i
8/10/2017Roth CapitalSet Price TargetBuy$200.00High
i
Rating by Michael Higgins at Roth Capital
8/3/2017Roth CapitalSet Price TargetBuy$200.00Low
i
Rating by Michael Higgins at Roth Capital
5/24/2017Maxim GroupSet Price TargetBuy$180.00Low
i
Rating by Jason Kolbert at Maxim Group
3/24/2017Maxim GroupReiterated RatingBuy$180.00Low
i
4/5/2016Maxim GroupReiterated RatingBuy$180.00N/A
i
(Data available from 3/8/2016 forward)
Intec Pharma logo
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program; and a feasibility agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.
Read More

Today's Range

Now: $3.95
$3.90
$4.06

50 Day Range

MA: $4.94
$3.72
$7.85

52 Week Range

Now: $3.95
$2.20
$15.82

Volume

707 shs

Average Volume

969,805 shs

Market Capitalization

$14.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Intec Pharma?

The following Wall Street research analysts have issued stock ratings on Intec Pharma in the last year: HC Wainwright, LADENBURG THALM/SH SH, Maxim Group, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for NTEC.

What is the current price target for Intec Pharma?

1 Wall Street analysts have set twelve-month price targets for Intec Pharma in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 229.1%. LADENBURG THALM/SH SH has the highest price target set, predicting NTEC will reach $13.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $13.00 for Intec Pharma in the next year.
View the latest price targets for NTEC.

What is the current consensus analyst rating for Intec Pharma?

Intec Pharma currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NTEC, but not buy more shares or sell existing shares.
View the latest ratings for NTEC.

What other companies compete with Intec Pharma?

Other companies that are similar to Intec Pharma include Kintara Therapeutics, Catabasis Pharmaceuticals, Aridis Pharmaceuticals, Regulus Therapeutics, Soligenix, Forward Pharma A/S, Appili Therapeutics, Cumberland Pharmaceuticals, PainReform, Guardion Health Sciences, Lixte Biotechnology, Pulmatrix, Akari Therapeutics, Trevi Therapeutics and Newron Pharmaceuticals.

How do I contact Intec Pharma's investor relations team?

Intec Pharma's physical mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company's listed phone number is 972-2586-4657 and its investor relations email address is [email protected] The official website for Intec Pharma is www.intecpharma.com.